Circulating tumor DNA profiling of patients with metastatic luminal HER2-low and HER2-0 breast cancer via next-generation sequencing.. JCO 43 , e13090-e13090 (2025). DOI: ...

Circulating tumor DNA profiling of patients with metastatic luminal HER2-low and HER2-0 breast cancer via next-generation sequencing. Previous. NEXT ARTICLE. The role of ...

Omitting carboplatin from neoadjuvant treatment can improve safety without compromising efficacy in patients with HER2-positive early breast cancer.

Novartis Canada is pleased to announce that Health Canada has granted a Notice of Compliance (NOC) for KISQALI® (ribociclib ...

Trastuzumab deruxtecan plus pertuzumab showed significant improvement in PFS compared with taxane chemotherapy plus ...

Vepdegestrant shows significant progression-free survival benefits over fulvestrant in advanced breast cancer, highlighting ...

University of Cambridge study shows how LLM GPT-4 can generate novel combinations of drugs not typically used to treat cancer ...

Vepdegestrant significantly improved progression-free survival in ESR1-mutant ER-positive, HER2-negative advanced breast cancer compared to Faslodex, with a median of 5.0 months versus 2.1 months. The ...

Metastatic HER2-Positive Breast Cancer Market Metastatic HER2-Positive Breast Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, ...

In the DESTINY-Breast09 trial, presented at this year's American Society of Clinical Oncology (ASCO) annual meeting, ...

Inavolisib (Itovebi) is a new targeted therapy for HR+ HER2-negative metastatic breast cancer with a PIK3CA mutation.